2023-11-15T18:38:48-05:00 2022-12-31 203746583 TAYLOR ROTH AND COMPANY 800 GRANT ST STE 205 DENVER CO 802032944 990 2022-01-01 852221062 ALK POSITIVE INC ALKP 6785769913 6595 ROSWELL RD SUITE G2310 ATLANTA GA 30238 KIRK SMITH PRESIDENT 6785769913 2023-11-15 true KIRK SMITH 999009999 false KEN ROTH P01389203 3038308109 2023-11-15 2022 2023-04-26 12:10:37Z KIRK SMITH 6595 ROSWELL RD SUITE G2310 ATLANTA GA 30238 1602191 false X WWW.ALKPOSITIVE.ORG X 2020 DE TO IMPROVE THE LIFE EXPECTANCY AND QUALITY OF LIFE FOR ALK-POSITIVE CANCER PATIENTS WORLDWIDE. AS AN ONLINE PATIENT-LED ORGAIZATION IN OVER 70 COUNTRIES, WE OFFER PATIENT RESEARCH, EDUCATION, RESOURCES AND AWARENESS. 12 12 2 110 0 1793039 1596649 0 5542 0 1793039 1602191 0 0 76731 0 30375 104914 465010 104914 541741 1688125 1060450 3416376 4507425 2585 33184 3413791 4474241 X TO IMPROVE THE LIFE EXPECTANCY AND QUALITY OF LIFE FOR ALK-POSITIVE CANCER PATIENTS WORLDWIDE. AS AN ONLINE PATIENT-LED ORGAIZATION IN OVER 70 COUNTRIES, WE OFFER PATIENT RESEARCH, EDUCATION, RESOURCES AND AWARENESS. false false 454398 ALK POSITIVE, INC. IS A PATIENT DRIVEN 501(C)(3) NONPROFIT CORPORATION PROVIDING SUPPORT, EMPATHY AND RESEARCH FUNDING TO CHANGE THE FUTURE FOR ALK-POSITIVE CANCER PATIENTS. ALK-POSITIVE CANCER IS ESTIMATED TO OCCUR IN APPROXIMATELY 100,000 PATIENTS WORLDWIDE EVERY YEAR. ALTHOUGH THE VAST MAJORITY OF CASES OCCUR AS LUNG CANCER, IT CAN ALSO ORIGINATE IN MANY OTHER ORGANS. THE MEDIAN AGE FOR ALK-POSITIVE PATIENTS AT DIAGNOSIS IS ABOUT 50 YEARS WITH MANY IN THEIR FORTIES, THIRTIES AND EVEN YOUNGER. APPROXIMATELY 55% OF ALK-POSITIVE PATIENTS ARE FEMALE AND THE DISEASE OCCURS WITH PEOPLE OF ALL RACES. ---------------------- SEE SCHEDULE O ---------------------------------- 454398 true true false false false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 4 0 true 2 true false false false false false false false false false false false false X 12 12 false false false false false false false true true false false true true true true true true true false false X THE ORGANIZATION 2087901106 6595 ROSWELL RD STE G2310 ATLANTA GA 30328 LONNA SMITH EXECUTIVE DI 40.00 X 12500 0 0 SCOTT SCHELL CEO 40.00 X 92811 0 0 KIRK SMITH PRESIDENT 5.00 X X 0 0 0 NANCEE PRONSATI VICE PRESIDE 5.00 X X 0 0 0 CHRISTINA WEBER SECRETARY 5.00 X X 0 0 0 CLARK EVANS TREASURER 5.00 X X 0 0 0 JT HEDGES DIRECTOR 2.00 X 0 0 0 TERESA WIANT DIRECTOR 2.00 X 0 0 0 JAMIE GIBBARD DIRECTOR 2.00 X 0 0 0 PATTY SACCENTI DIRECTOR 2.00 X 0 0 0 GREG WEHN DIRECTOR 2.00 X 0 0 0 DUNCAN PREECE DIRECTOR 2.00 X 0 0 0 SUMMER FARMEN DIRECTOR 2.00 X 0 0 0 MARC MUSKAVITCH DIRECTOR 2.00 X 0 0 0 BILL WESTLAKE PRESIDENT 5.00 X X 0 0 0 AMANDA NERSTAD VICE PRESIDE 5.00 X X 0 0 0 GINA HOLLENBECK DIRECTOR 2.00 X 0 0 0 COLIN BARTON DIRECTOR 2.00 X 0 0 0 105311 false false false 1596649 1596649 3366 1937 1429 2176 2176 2176 2176 1602191 1937 3605 X 12500 10000 1250 1250 58739 46991 5874 5874 5492 4394 549 549 14711 14711 155020 125237 15851 13932 21862 19676 2186 35162 30088 1733 3341 375 375 23460 21114 2346 4389 3950 439 4804 4804 PROGRAM SUPPLIES 126960 126960 RESEARCH CONTRACTS 51767 51767 ORGANIZATION DEVELOPMENT 17000 17000 SECOND OPINION PROGRAM 4920 4920 4580 4122 458 541741 454398 56968 30375 3261437 3675960 279114 153903 152656 16610 1036 957 378816 3312 3416376 4507425 2585 33184 2585 33184 X 746074 1527106 2667717 2947135 3413791 4474241 3416376 4507425 1060450 X false true X true false X 1793039 1596649 3389688 1793039 1596649 3389688 478712 2910976 1429 1429 3391117 1937 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1602191 1602191 1602191 541741 541741 541741 FORM 990, PART III IN 2017, SOME ALK-POSITIVE CANCER PATIENTS AND CAREGIVERS FORMED THE OUTREACH MANAGEMENT GROUP TO PARTNER WITH THE LUNGEVITY FOUNDATION IN ORDER TO RAISE FUNDS FOR CANCER RESEARCH. IN 2018, THE PARTNERSHIP WAS FORMALIZED INTO A JOINT FUNDRAISING AND RESEARCH AGREEMENT WITH BOTH LUNGEVITY AND THE GO2 FOUNDATION FOR LUNG CANCER. FROM 2017 TO 2021, THE PARTNERSHIPS GENERATED OVER 4.7M IN CONTRIBUTIONS AND AWARDED 2.8M IN TRANSLATIONAL RESEARCH GRANTS WITH THE PURPOSE OF IMPROVING ALK-POSITIVE CANCER PATIENT OUTCOMES. BY MARCH 2021, THE OUTREACH MANAGEMENT GROUP HAD INCORPORATED AND WAS RECOGNIZED BY THE IRS AS A 501(C)(3) NON PROFIT ORGANIZATION CALLED ALK POSITIVE INC. DURING 2021-22 ANOTHER 3.4M IN CONTRIBUTIONS WAS GENEROUSLY RAISED WITH RESEARCH GRANTS TOTALING 2.6M AWARDED. ALSO IN 2022, THE FIRST TWO EMPLOYEES WERE HIRED - A DIRECTOR OF RESEARCH AND CLINICAL AFFAIRS, AND AN EXECUTIVE DIRECTOR. THE MISSION OF ALK POSITIVE INC. IS TO IMPROVE THE LIFE EXPECTANCY AND QUALITY OF LIFE FOR ALK-POSITIVE CANCER PATIENTS WORLDWIDE. AS AN ONLINE PATIENT-LED ORGANIZATION IN OVER 70 COUNTRIES, THE ORGANIZATION OFFERS PATIENT RESEARCH, EDUCATION, RESOURCES AND AWARENESS PROGRAMS TO MEET ITS MISSION OBJECTIVES. BY FAR THE MOST EFFECTIVE TREATMENTS FOR ALK-POSITIVE CANCER ARE THE ORAL ALK TYROSINE KINASE INHIBITORS (TKI'S). THESE ARE NOW FDA APPROVED IN 1ST, 2ND AND 3RD GENERATION VERSIONS, EACH GENERATION MORE EFFECTIVE THAN THE PREVIOUS. HOWEVER, WHILE TKI'S HAVE IMPROVED MEDIAN OVERALL SURVIVAL FROM A FEW MONTHS TO MANY YEARS, ALK-POSITIVE CANCERS INEVITABLY MUTATE AND BECOME RESISTANT TO ALL TKIS. THE ORGANIZATION CREATED THE RESEARCH REVIEW PANEL (COMMITTEE) COMPRISING VOLUNTEER ALK-POSITIVE CANCER PATIENTS, CAREGIVERS AND WORLD-RENOWNED SCIENTIFIC AND RESEARCH EXPERTS TO HELP REVIEW AND AWARD THE MOST PROMISING ALK-POSITIVE CANCER RESEARCH PROJECTS TO IMPROVE PATIENT OUTCOMES. IN 2022, THIS RESEARCH TEAM WAS EXPANDED TO: - RESEARCH ACCELERATION COMMITTE: ACCELERATE ACADEMIC AND BIOTECH RESEARCH THAT LEADS TO NEW THERAPIES FOR ALK+ PATIENTS, INCLUDING IMMUNOTHERAPIES AND COMBINATION THERAPIES, AND NEW CLINICAL TRIALS, VIA COLLABORATION WITH ACADEMIA, INDUSTRY, AND VENTURE CAPITAL. - CLINICAL TRIALS COMMITTEE: COLLABORATE WITH ACADEMIA AND INDUSTRY TO DEVELOP NEW FRAMEWORKS FOR CLINICAL TRIALS AND TO ACCELERATE CREATION, EFFECTIVE ENROLLMENT AND SUCCESSFUL READOUTS FOR CLINICAL TRIALS INVOLVING AND BENEFICIAL TO ALK+ PATIENTS. - TRANSLATIONAL INVESTIGATIONS GROUP: FRAME AND IMPLEMENT AN INTERNAL ALK-POSITIVE RESEARCH PROGRAM THAT ADDRESSES KEY QUESTIONS FOR WHICH ANSWERS WILL ENABLE THE DEVELOPMENT OF NEW ALK THERAPIES, BIOMARKERS OF TREATMENT RESPONSE AND ACCELERATED CLINICAL TRIALS. FORM 990, PAGE 6, PART VI, LINE 11B THE BOARD WILL REVIEW THE FORM 990 PRIOR TO FILING WITH THE IRS. FORM 990, PAGE 6, PART VI, LINE 12C BOARD MEMBERS SIGN A COPY OF THE CONFLICT OF INTEREST FORM ANNUALLY. FORM 990, PAGE 6, PART VI, LINE 15A COMPENSATION FOR THE EXECUTIVE DIRECTOR WAS BASED ON RESEARCH ONLINE, COMMITTEE AND BOARD DISCUSSIONS, AND DISCUSSIONS WITH THE EXECUTIVE RECRUITING COMPANY. FORM 990, PAGE 6, PART VI, LINE 19 GOVERNING AND FINANCIAL DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G PROFESSIONAL SERVICE 14,864 851 0 CONTRACT CEO 110,373 15,000 13,932 TOTAL 125,237 15,851 13,932